CSF2 and rheumatoid arthritis: Mavrilimumab is a monoclonal antibody against granulocyte–macrophage colony-stimulating factor (GM-CSF), and GM-CSF is expressed at high levels in synovial fluid and plasma as well as synovial tissue cells of RA patients.